Megan R Paul1, Victor Wong1, Paula Aristizabal1,2, Dennis J Kuo1. 1. Department of Pediatrics, Division of Pediatric Hematology-Oncology, University of California San Diego, Peckham Center for Cancer and Blood Disorders, Rady Children's Hospital San Diego, San Diego. 2. Department of Populations Sciences, Disparities, and Community Outreach and Engagement, University of California San Diego, Moores Cancer Center, La Jolla, CA.
Abstract
BACKGROUND: Inotuzumab ozogamicin is a novel antibody-drug conjugate that targets CD22, a common antigen on pre-B acute lymphoblastic leukemia cells. OBSERVATIONS: A 7-year-old boy with pre-B acute lymphoblastic leukemia in his second relapse was given 2 cycles of inotuzumab ozogamicin. He responded morphologically with a negative bone marrow evaluation. However, he relapsed in cycle 3 of therapy with a loss of CD22 expression on his lymphoblast population. CONCLUSION: To our knowledge, this is the first published case of CD22 expression loss as a mechanism of therapy resistance for inotuzumab ozogamicin.
BACKGROUND:Inotuzumabozogamicin is a novel antibody-drug conjugate that targets CD22, a common antigen on pre-Bacute lymphoblastic leukemia cells. OBSERVATIONS: A 7-year-old boy with pre-Bacute lymphoblastic leukemia in his second relapse was given 2 cycles of inotuzumabozogamicin. He responded morphologically with a negative bone marrow evaluation. However, he relapsed in cycle 3 of therapy with a loss of CD22 expression on his lymphoblast population. CONCLUSION: To our knowledge, this is the first published case of CD22 expression loss as a mechanism of therapy resistance for inotuzumabozogamicin.
Authors: Sabine Kayser; Chiara Sartor; Marlise R Luskin; Jonathan Webster; Fabio Giglio; Nydia Panitz; Andrew M Brunner; Matthias Fante; Christoph Lutz; Daniel Wolff; Anthony D Ho; Mark J Levis; Richard F Schlenk; Cristina Papayannidis Journal: Haematologica Date: 2022-09-01 Impact factor: 11.047